ANNALS OF ONCOLOGY

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.

Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma

Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

Docetaxel for hormone-naive prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden

Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study

The analysis of current treatment outcomes in melanoma patients with brain metastases

A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer

The effect of cortisol on methylation patterns in breast cancer cell lines

Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients

Findings from a new specialist remote counselling service for neuroendocrine neoplasm (NEN) patients and family members

Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients: A prospective multicenter trial

Characterisation of growth hormone signal transduction in primary melanoma cell lines

Molecular profiling and prognostic significance of TP53 mutations in diffuse large b cell lymphoma: Identifying a high-risk subgroup

Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

JAK2 (V617F) positively regulates PD-L1 mRNA expression via STAT3/5 activation in MNP (PV and ET) patients

Gefitinib along with methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients

Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC

Drug selection by Narrative approach in patients with advanced gastric cancer -Paclitaxel or nab-Paclitaxel?-

Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)

Impact of donor lymphocyte infusion in relapsing myeloid neoplasms post allogeneic hematopoietic stem cell transplantation

PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications

Impact of cognitive-behavioral-therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)

Combination treatment of astragalus membranaceus, dose-modified chemotherapy, and anti-PD1 checkpoint inhibitor for patients of advanced malignancy with initial cachexia or poor performance status: A single-institute experience

Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group

Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis

Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21

Re-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective

Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer

Comparison between phase III randomized clinical trials and their preceeding phase II studies

Evaluating the role of clinical nurse specialist

Prevalance Geriatric in Hospitilized Cancer Patient

Scalp cooling with Cool Cap can palliate or avoid alopecia of adverse event by chemotherapy for breast cancer

High incidence and mortality of transitional cell carcinoma in Thai kidney transplant patients

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study

The tyrosine kinase inhibitor dasatinib blocks tumour growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer

Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research

A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma

Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility

ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure

Effective treatment with T-VEC monotherapy in stage IIIB/C-IVM1a melanoma of the head & neck region

An analysis of 30-day mortality after the last cycle of immune checkpoint inhibitors treatment